Micvotabart pelidotin (MICVO) + KEYTRUDA®

About Pyxis Oncology

Pyxis Oncology's mission is to liberate science to cure patients with cancer through a disruptive approach that improves and extends life. The company has achieved key milestones including positive preliminary Phase 1 data for its lead ADC, MICVO, and securing FDA Fast Track Designation for recurrent/metastatic head and neck squamous cell carcinoma. Its strategy centers on developing a portfolio of next-generation ADCs and immunotherapies, with a core focus on novel extracellular matrix targets to overcome limitations of conventional therapies. Pyxis is publicly traded, maintains a lean operational structure, and is led by an experienced management team with a track record in oncology drug development.

Therapeutic Areas